Brandes DW - Search Results

1

A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events.

Brandes DW, Callender T, Lathi E, O'Leary S. Brandes DW, et al. Curr Med Res Opin. 2009 Jan;25(1):77-92. doi: 10.1185/03007990802569455. Curr Med Res Opin. 2009. PMID: 19210141 Review.

2

Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: a pilot study.

Brandes DW, Bigley K, Hornstein W, Cohen H, Au W, Shubin R. Brandes DW, et al. Curr Med Res Opin. 2007 Jul;23(7):1667-72. doi: 10.1185/030079907x210741. Curr Med Res Opin. 2007. PMID: 17588298 Clinical Trial.

3

Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis.

Moses H Jr, Brandes DW. Moses H Jr, et al. Among authors: brandes dw. Curr Med Res Opin. 2008 Sep;24(9):2679-90. doi: 10.1185/03007990802329959. Epub 2008 Aug 8. Curr Med Res Opin. 2008. PMID: 18694542

4

Implications of real-world adherence on cost-effectiveness analysis in multiple sclerosis.

Brandes DW, Raimundo K, Agashivala N, Kim E. Brandes DW, et al. J Med Econ. 2013;16(4):547-51. doi: 10.3111/13696998.2013.774281. Epub 2013 Feb 21. J Med Econ. 2013. PMID: 23391123 Free article.

5

Invited commentary. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.

Brandes DW. Brandes DW. Neurol India. 2009 Jul-Aug;57(4):423-4. Neurol India. 2009. PMID: 19827223 Free article. No abstract available.

6

The role of glatiramer acetate in the early treatment of multiple sclerosis.

Brandes DW. Brandes DW. Neuropsychiatr Dis Treat. 2010 Jun 24;6:329-36. doi: 10.2147/ndt.s5898. Neuropsychiatr Dis Treat. 2010. PMID: 20628633 Free PMC article.

7

Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.

Agashivala N, Wu N, Abouzaid S, Wu Y, Kim E, Boulanger L, Brandes DW. Agashivala N, et al. Among authors: brandes dw. BMC Neurol. 2013 Oct 4;13:138. doi: 10.1186/1471-2377-13-138. BMC Neurol. 2013. PMID: 24093542 Free PMC article.

8

Treatment selection and experience in multiple sclerosis: survey of neurologists.

Hanson KA, Agashivala N, Wyrwich KW, Raimundo K, Kim E, Brandes DW. Hanson KA, et al. Among authors: brandes dw. Patient Prefer Adherence. 2014 Apr 3;8:415-22. doi: 10.2147/PPA.S53140. eCollection 2014. Patient Prefer Adherence. 2014. PMID: 24729689 Free PMC article.

9

A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod.

Hanson KA, Agashivala N, Stringer SM, Balantac Z, Brandes DW. Hanson KA, et al. Among authors: brandes dw. Patient Prefer Adherence. 2013 Apr 16;7:309-18. doi: 10.2147/PPA.S41992. Print 2013. Patient Prefer Adherence. 2013. PMID: 23620662 Free PMC article.

10

Quantifying the role of natalizumab in health and economic outcomes in multiple sclerosis.

Brandes DW, Shaya FT, Pill MW. Brandes DW, et al. Am J Manag Care. 2010 Jun;16(6 Suppl):S171-7. Am J Manag Care. 2010. PMID: 20615053 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters